[Federal Register Volume 82, Number 47 (Monday, March 13, 2017)]
[Notices]
[Page 13460]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-04834]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the patent applications listed below may be obtained by communicating 
with the indicated licensing contact at the Technology Transfer and 
Intellectual Property Office, National Institute of Allergy and 
Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required 
to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

N6, A Novel, Broad, Highly Potent HIV-Specific Antibody

Description of Technology

    The N6 antibody has evolved a unique mode of binding that depends 
less on a variable area of the HIV envelope known as the V5 region and 
focuses more on conserved regions, which change relatively little among 
HIV strains. This allows N6 to tolerate changes in the HIV envelope, 
including the attachment of sugars in the V5 region, a major mechanism 
by which HIV develops resistance to other VRC01-class antibodies. N6 
was shown in pre-clinical studies to neutralize approximately 98 
percent of HIV isolates tested. The studies also demonstrate that N6 
neutralizes approximately 80 percent of HIV isolates which were 
resistant to other antibodies of the same class, and does so very 
potently. Its breadth and potency makes N6 a highly desirable candidate 
for development in therapeutic or prophylactic strategies.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.

Potential Commercial Applications

     HIV therapeutic
     HIV prophylactic

Competitive Advantages

     Neutralized 98 percent of HIV isolates tested.
     Neutralized 80 percent of HIV isolates which were 
resistant to other antibodies of the same class, and does so very 
potently.
    Development Stage: Pre-Clinical.
    Inventors: Mark Connors, Jinghe Huang, Byong Ha Kang, John Mascola, 
Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng, all of NIAID.
    Publications: Huang, Jinghe, et al. ``Identification of a CD4-
binding-site antibody to HIV that evolved near-pan neutralization 
breadth.'' Immunity 45.5 (2016): 1108-1121.
    Intellectual Property: HHS Reference No. E-131-2015 et seq.--US 
provisional application 62/136,228, US provisional application 62/
250,378, and PCT application PCT/US2016/023145.
    Licensing Contact: Chris Kornak, 240-627-3705, 
[email protected].
    Collaborative Research Opportunity: The Technology Transfer and 
Intellectual Property Office (TTIPO) is seeking parties interested in 
collaborative research to further co-develop this technology. For 
collaboration opportunities, please contact Chris Kornak, 240-627-3705, 
[email protected].

    Dated: March 3, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-04834 Filed 3-10-17; 8:45 am]
 BILLING CODE 4140-01-P